The first batch of H1N1 influenza vaccines
Posted on June 17, 2009
Filed Under H1N1 Prevention, H1N1 Treatment & Drugs | Leave a Comment
The international pharmaceutical giant Novartis announced on the 12th, the company has successfully granted the system Chutou Influenza H1N1 influenza vaccines. Vaccination program in July to implement clinical trials to obtain production licenses put into mass production later in September.
Pre-empt the use of cell technology is made more than 30 countries pre-empt the Order
Novartis said in a statement on the 12th: “Novartis has successfully completed the first batch of Influenza A H1N1 influenza vaccine production in a few weeks earlier than expected time.” Most of the media and analysts previously forecast, Influenza H1N1 influenza vaccine may come out in August. Novartis said in a statement, the company expects in July to implement clinical trials of influenza vaccine as soon as possible after the production licenses. Agence France-Presse by refusing to be named Novartis management personnel sources, now more than 30 countries have been ordered to Novartis Vaccines, Novartis hopes that in September or October in volume production.
The Associated Press reported that using cell technology to cultivate Novartis H1N1 influenza vaccines, without using eggs, traditional methods of cultivating the vaccine. At this stage, the world’s only less than 5% of the vaccine from cell technology to cultivate. However, the United States Vaccine Research, University of Virginia scholar戴维弗德森that the next few years, the main use of the world’s influenza vaccine will continue to nurture eggs law, “the short-term cell technology will not speed up the rate of production of vaccines.”
The statement said that the first “baked” vaccine by Novartis, based in Marburg, Germany plant production, the first batch of 10 liters of the vaccine into the first laboratory tests, re-enter clinical trials. The company also plans to build a new North Carolina plant, the production Influenza H1N1 influenza vaccine.
A number of pharmaceutical giants to compete for
Influenza A H1N1 influenza outbreak occurred, the number of international pharmaceutical giant, is committed to developing this type of new influenza vaccines. Novartis announced on the 12th the system out of the vaccine the same day, the United Kingdom GlaxoSmithKline – GSK company said that the company 4-6 months out of the system for Influenza A H1N1 influenza vaccine. GlaxoSmithKline – GSK previously agreed to provide 50 million free World Health Organization H5N2 avian influenza vaccine, now decided to instead go to the WHO donated the same amount of Influenza A H1N1 influenza vaccine. Another French international pharmaceutical giants Sanofi – Pasteur company also announced that the company will soon come up with Sanofi – Pasteur version of the Influenza A H1N1 influenza vaccine.
WHO spokeswoman for France Delachat Ibb 12, told reporters in Geneva, Switzerland, WHO intends to have the world’s production of influenza vaccine to all pharmaceutical companies qualified to provide Influenza H1N1 influenza virus strains for these enterprises to cultivate the use of vaccines. WHO predicts that a year later, approximately 2.4 billion Influenza A H1N1 influenza vaccine can be plowed into the global market.
Comments
Leave a Reply